3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Venous Thromboembolism
12
Venous Thrombosis
9
Pulmonary Embolism
9
Neoplasms
8
Thrombosis
4
Pancreatic Neoplasms
3
Multiple Myeloma
3
Lung Neoplasms
3
Thromboembolism
2
Neoplasm Metastasis
2
Lymphoma
2
Hemorrhage
2
Colorectal Neoplasms
2
Uterine Cervical Neoplasms
1
Thrombophilia
1
Thrombocytopenia
1
Thrombocythemia, Essential
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Ovarian Neoplasms
1
Obesity
1
Neoplasms, Plasma Cell
1
Myeloproliferative Disorders
1
Interventions
Gemcitabine
39
Cisplatin
24
Oxaliplatin
21
Capecitabine
20
Fluorouracil
11
Leucovorin
9
Irinotecan
9
130-nm albumin-bound paclitaxel
8
durvalumab
6
Taxes
5
Radiotherapy
5
Platinum
4
Immunohistochemistry
4
Erlotinib Hydrochloride
4
Docetaxel
4
Carboplatin
4
Bevacizumab
4
Albumin-Bound Paclitaxel
4
1,2-diaminocyclohexaneplatinum II citrate
4
trifluridine tipiracil drug combination
3
Trastuzumab
3
Sorafenib
3
Observation
3
Epirubicin
3
Drug Therapy
3
tremelimumab
2
toripalimab
2
regorafenib
2
pembrolizumab
2
anlotinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Gallbladder Neoplasms
×
Dalteparin
×
Clear all
NCT03139487
2020-01-06
PRIORITY
Asan Medical Center
Phase 2
Unknown
176 enrolled